2022 ASCO Highlights
Below please find highlights of key advances in cancer research and an overview of Dana-Farber faculty presentations at ASCO.
Harold Burstein, MD, PhD on key advances from ASCO 2022
Harold Burstein, MD, PhD shares key highlights of research advances from the American Society of Clinical Oncology annual conference #ASCO22.
Harold Burstein, MD, PhD on advances in breast cancer research from ASCO 2022
Harold Burstein, MD, PhD shares key highlights of research advances in breast cancer from the American Society of Clinical Oncology annual conference #ASCO22.
ASCO22: Breast cancer research by Sara Tolaney, MD
Breast cancer phase 3 study results TROPiCS-02 at #ASCO22: Dana-Farber's Sara Tolaney, MD, senior author, says research shows new antibody-drug conjugate produced improved progression-free survival rates compared to chemotherapy in HR+/HER2-neg ...
ASCO22: Pasi Janne, MD, PhD on lung cancer research
Lung cancer research at #ASCO22. Non-small cell lung cancers with KRAS mutation respond to experimental drug adagrasib which also shows activity in brain metastasis. Dana-Farber's Pasi Janne, MD, PhD, is senior author and explains more.
ASCO22: Lung Cancer session by Jia Luo, MD
Lung cancer research targeting KRAS in non–small cell lung cancer. Dana-Farber's Jia Luo, MD discusses KRAS lung cancer treatments and exciting research in the field.
ASCO22: Glioblastoma research by David Reardon, MD
Glioblastoma study shows combination immunotherapy is safe and early data on effectiveness is encouraging. Dana-Farber's David Reardon, MD, details more at #ASCO22 about the combination of a potent vaccine platform with immune checkpoint blockade.
ASCO22: Kidney Cancer research by Toni Choueiri, MD
New data on adjuvant pembrolizumab after kidney cancer surgery presented by Dana-Farber's Toni Choueiri, MD, at #ASCO22.
ASCO22: Breast cancer research by Meredith Regan, ScD
Dana-Farber's Meredith Regan, ScD presents research looking at early treatment effects of adjuvant endocrine therapy for high-risk breast cancer at #ASCO22.
ASCO22: Marla Lipsyc-Sharf, MD on ctDNA in breast cancer
Using ctDNA found with liquid biopsy to understand recurrence risk in hormone receptor-positive breast cancer. Dana-Farber's Marla Lipsyc-Sharf MD, details research presented at #ASCO22 and published in the Journal of Clinical Oncology.
ASCO22: Breast cancer research by Chris Labaki, MD
Dana-Farber's Chris Labaki, MD details how Real-World Progression-Free Survival and Time to Next Line of Therapy may be useful intermediate endpoints for survival in patients with advanced breast cancer.
ASCO22: Chris Manz, MD on AI in oncology
Artificial intelligence as a tool to increase discussions between patients and their oncology team about care goals can improve end-of-life care, according to research at led by Dana-Farber's Chris Manz, MD and presented at #ASCO22.
ASCO2022: Multiple Myeloma Research by Dr. Paul Richardson
Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: a study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be ...